Unique ID issued by UMIN | UMIN000028386 |
---|---|
Receipt number | R000032494 |
Scientific Title | Efficacy and Safety of A0001 for Anterior Capsule Staining: Phase III Investigator-initiated Multicenter Clinical Trial |
Date of disclosure of the study information | 2017/08/07 |
Last modified on | 2018/07/27 09:32:48 |
Efficacy and Safety of A0001 for Anterior Capsule Staining: Phase III Investigator-initiated Multicenter Clinical Trial
Efficacy and Safety of A0001 for Anterior Capsule Staining
Efficacy and Safety of A0001 for Anterior Capsule Staining: Phase III Investigator-initiated Multicenter Clinical Trial
Efficacy and Safety of A0001 for Anterior Capsule Staining
Japan |
Refractory cataract
Ophthalmology |
Others
NO
Visualization of the anterior capsule using A0001 during cataract surgery
Efficacy
Others
Pragmatic
Phase III
Central evaluation of the efficacy of A0001 administered to anterior camber for visualization of the anterior capsule during cataract surgery.
-Evaluation of degree of visualization and evaluation of ease of operation by surgeon.
-Evaluation of the safety of A0001 based on data of adverse effects, side effects, ophthalmological examinations.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
NO
Institution is not considered as adjustment factor.
NO
1
Treatment
Medicine |
Brilliant Blue G250
20 | years-old | <= |
Not applicable |
Male and Female
There are indications for cataract surgery for one eye or both eyes, and cataract with severe cortical cataract, mature cataract, hyperzagmus cataract, cataract with corneal opacity, cataract with vitreous opacity, etc. Cataract in which it is difficult to see the anterior capsule of the lens in normal cataract surgery.
1) IOL implanted eye.
2) Has serious of digestive, circulatory, kidney, liver, or blood/coagulation complications
3) Had present and past uveitis or glaucoma
4) Those who fall under Grade 3 or Grade 4 in the classification of "Grading for Corneal Endothelial Damage (2014) "prescribed by the Japan Corneal Society. However, cases where it is difficult to measure the number of corneal endothelial cells by corneal clouding or the like can be incorporated.
5) Patient of Bullous keratopathy
6) Has a history of drug hypersensitivity reactions for mydriatic, antibacterial eyedrops or local anesthetic.
7) Has a history of drug or alcohol abuse
8) Had taken this clinical trial
9) Those who participated in other clinical trials or clinical studies within 30 days before consent acquisition and received medication, or those planning to participate in other trials during this trial
8) Is deemed unsuitable for this trial by PI or SI
30
1st name | |
Middle name | |
Last name | Tatsuro Ishibashi |
Kyushu University Hospital
Director
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
092-642-5648
ishi@eye.med.kyushu-u.ac.jp
1st name | |
Middle name | |
Last name | Makiko Uchiyama |
Kyushu University Hospital
Center for Clinical and Translational Research
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
092-642-6291
m-uchi@med.kyushu-u.ac.jp
Kyushu University Hospital
Japan Agency for Medical Research and Development
Japanese Governmental office
Japan
NO
杏林大学医学部付属病院、大阪大学医学部附属病院、滋賀医科大学附属病院、奈良県立医科大学附属病院、山口大学医学部附属病院、大分大学医学部附属病院、大島眼科病院
2017 | Year | 08 | Month | 07 | Day |
Unpublished
Completed
2017 | Year | 06 | Month | 17 | Day |
2017 | Year | 09 | Month | 15 | Day |
2018 | Year | 04 | Month | 30 | Day |
2017 | Year | 07 | Month | 26 | Day |
2018 | Year | 07 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032494